Cross-Platform Notification Demo
Simulating Patient Experience on sites.eligara.ai
When a study coordinator on recruit.eligara.ai sends an inquiry to a basket candidate, this is what the patient or their oncologist sees inside their personal case view on sites.eligara.ai.
← Return to Recruiter Tracker
https://sites.eligara.ai/cases/case-9481-a7b2
Logged in as: eleanor.vance@gmail.com
Eligara
Home Cases Favourites Clinical Trials
1
EV
Eleanor Vance
Patient Case Record (Private)

Alice Johnson Telescope

Stage IV Non-Small Cell Lung Cancer (EGFR Exon 19 del) • Created on sites.eligara.ai
🔔
New Recruiter Inquiry
A Study Coordinator has expressed interest in your case!
Recruiting Trial NCT05481234

Phase 2 Study of Targeted Combination Therapy in EGFR-Mutated Advanced NSCLC

Research Center: Dana-Farber Cancer Institute (Center for Thoracic Oncology) • Boston, MA
Personalized Message from Study Coordinator Dr. Sarah Chen:

"Dear Patient, our clinical research team at Dana-Farber Cancer Institute reviewed your de-identified case summary on Eligara and identified your clinical profile as a potential match for our enrolling targeted therapy trial (NCT05481234: Osimertinib + Combination in EGFR-Mutant NSCLC). If you are interested in exploring whether this trial could be an appropriate next step in your treatment plan, please tap 'I am Interested in Connecting' below. We would be delighted to provide comprehensive trial documentation and discuss with you or your treating oncologist."

🛡️ Your personal contact details and name remain private. Clicking "I'm Interested in Connecting" securely shares your contact preference with Dr. Sarah Chen's study team.

Clinical Case Summary

62-year-old female diagnosed with metastatic lung adenocarcinoma in late 2024. Next-generation sequencing confirmed EGFR Exon 19 deletion. Completed 14 months of erlotinib with recent oligoprogression in right lower lobe. Stable brain metastasis treated with SRS...